Heart failure & cardiomyopathies
Cost-Utility Analysis of Add-On Dapagliflozin in Heart Failure with Preserved or Mildly Reduced Ejection Fraction
Authors' conclusion
From a public healthcare system perspective, the adjunct use of dapagliflozin to standard therapy among patients with HFpEF or HFmrEF generated advantages in cost-effectiveness in China at a WTP of $12 652.5/QALY
Study context
- Population
- 65-year-old patients with heart failure with preserved ejection fraction (HFpEF) or heart failure with mildly reduced ejection fraction (HFmrEF), Chinamodelled cohort
- Comparison
- Add-on dapagliflozin vs standard therapy
- Outcome
- Total cost and QALYs per patient, and incremental cost-effectiveness ratio
- Follow-up
- 15-year lifetime horizon
Methodological detailsMarkov model, five-state Markov model, 15-year lifetime horizon, public healthcare system perspective, discount rate 5%, Based on the DELIVER study and national statistical database
- Markov model
- Five-state Markov model
- 15-year lifetime horizon
- Public healthcare system perspective
- Discount rate 5%
- Based on the DELIVER study and national statistical database
Main finding
As reported in the abstract
Incremental cost
1838.22 $
Cost, quality-adjusted life-years (QALYs) and ICER per patient
Incremental QALYs
0.15 QALYs
Cost, QALYs and ICER per patient
Incremental cost-effectiveness ratio
11 865.33 $/QALY
below willingness-to-pay (WTP) of $12 652.5/QALY
Dapagliflozin
- Average cost per patient
- $7245.77
- Average QALYs per patient
- 6.00 QALYs
Standard
- Average cost per patient
- $5407.55
- Average QALYs per patient
- 5.84 QALYs
Average cost per patient
Average QALYs per patient
Further findings
Univariate sensitivity analysis
- CV death in both groups was the most sensitive variable
Probabilistic sensitivity analysis: probability dapagliflozin add-on is cost-effective
- At WTP $12 652.5/QALY
- 54.6%
- At WTP $37 957.5/QALY
- 71.6%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →